{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:23:38Z","timestamp":1790706218068,"version":"4.1.0"},"reference-count":82,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In current clinical practice, genetic testing to detect Lynch syndrome mutations ideally begins with diagnostic testing of an individual affected with cancer before offering predictive testing to at-risk relatives. An alternative strategy that warrants exploration involves screening unaffected individuals via demographic and family histories, and offering genetic testing to those individuals whose risks for carrying a mutation exceed a selected threshold. Whether this approach would improve health outcomes in a manner that is cost-effective relative to current standards of care has yet to be demonstrated. To do so, we developed a simulation framework that integrated models of colorectal and endometrial cancers with a 5-generation family history model to predict health and economic outcomes of 20 primary screening strategies (at a wide range of compliance levels) aimed at detecting individuals with mismatch repair gene mutations and their at-risk relatives. These strategies were characterized by (i) different screening ages for starting risk assessment and (ii) different risk thresholds above which to implement genetic testing. For each strategy, 100,000 simulated individuals, representative of the U.S. population, were followed from the age of 20, and the outcomes were compared with current practice. Findings indicated that risk assessment starting at ages 25, 30, or 35, followed by genetic testing of those with mutation risks exceeding 5%, reduced colorectal and endometrial cancer incidence in mutation carriers by approximately 12.4% and 8.8%, respectively. For a population of 100,000 individuals containing 392 mutation carriers, this strategy increased quality-adjusted life-years (QALY) by approximately 135 with an average cost-effectiveness ratio of $26,000 per QALY. The cost-effectiveness of screening for mismatch repair gene mutations is comparable to that of accepted cancer screening activities in the general population such as colorectal cancer screening, cervical cancer screening, and breast cancer screening. These results suggest that primary screening of individuals for mismatch repair gene mutations, starting with risk assessment between the ages of 25 and 35, followed by genetic testing of those whose risk exceeds 5%, is a strategy that could improve health outcomes in a cost-effective manner relative to current practice. Cancer Prev Res; 4(1): 9\u201322. \u00a92010 AACR. Cancer Prev Res; 4(1); 9\u201322. \u00a92010 AACR.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-10-0262","type":"journal-article","created":{"date-parts":[[2010,11,19]],"date-time":"2010-11-19T00:35:27Z","timestamp":1290126927000},"page":"9-22","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population"],"prefix":"10.1158","volume":"4","author":[{"given":"Tuan A.","family":"Dinh","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Archimedes, Inc., San Francisco, California; 2GI Cancer Research Laboratory, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas; 3Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 5Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan; and 6Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin I.","family":"Rosner","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Archimedes, Inc., San Francisco, California; 2GI Cancer Research Laboratory, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas; 3Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 5Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan; and 6Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Atwood","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Archimedes, Inc., San Francisco, California; 2GI Cancer Research Laboratory, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas; 3Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 5Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan; and 6Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Richard","family":"Boland","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Archimedes, Inc., San Francisco, California; 2GI Cancer Research Laboratory, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas; 3Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 5Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan; and 6Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Syngal","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Archimedes, Inc., San Francisco, California; 2GI Cancer Research Laboratory, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas; 3Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 5Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan; and 6Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans F. A.","family":"Vasen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Archimedes, Inc., San Francisco, California; 2GI Cancer Research Laboratory, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas; 3Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 5Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan; and 6Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Gruber","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Archimedes, Inc., San Francisco, California; 2GI Cancer Research Laboratory, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas; 3Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 5Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan; and 6Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall W.","family":"Burt","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Archimedes, Inc., San Francisco, California; 2GI Cancer Research Laboratory, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas; 3Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 4Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 5Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan; and 6Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,1,3]]},"reference":[{"key":"2022060816022970900_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/GIM.0b013e31818fa2db","article-title":"EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome","volume":"11","author":"Palomaki","year":"2009","journal-title":"Genet Med"},{"key":"2022060816022970900_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/107327480901600103","article-title":"Endometrial cancer and Lynch syndrome: clinical and pathologic considerations","volume":"16","author":"Meyer","year":"2009","journal-title":"Cancer Control"},{"key":"2022060816022970900_bib3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1053\/gast.1996.v110.pm8612988","article-title":"Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis","volume":"110","author":"Vasen","year":"1996","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib4","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.296.12.1479","article-title":"Prediction of germline mutations and cancer risk in the Lynch syndrome","volume":"296","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"2022060816022970900_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cgh.2010.03.010","article-title":"Underdiagnosis of Lynch syndrome involves more than family history criteria","volume":"8","author":"Singh","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022060816022970900_bib6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1542-3565(04)00352-0","article-title":"Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients","volume":"2","author":"Grover","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022060816022970900_bib7","first-page":"137","article-title":"Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer","volume":"24","author":"Renkonen-Sinisalo","year":"2000","journal-title":"Cancer Detect Prev"},{"key":"2022060816022970900_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0016-5085(00)70168-5","article-title":"Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer","volume":"118","author":"Jarvinen","year":"2000","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMoa052627","article-title":"Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome","volume":"354","author":"Schmeler","year":"2006","journal-title":"N Engl J Med"},{"key":"2022060816022970900_bib10","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1200\/JCO.2003.03.189","article-title":"American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022060816022970900_bib11","first-page":"362","article-title":"Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S","volume":"143","author":"Nelson","year":"2005","journal-title":"Preventive Services Task Force. Ann Intern Med"},{"key":"2022060816022970900_bib12","article-title":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology.","year":"2010","journal-title":"Genetic\/Familial High Risk Assessment: Breast and Ovarian Cancer."},{"key":"2022060816022970900_bib13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2009.27.0660","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility","volume":"28","author":"Robson","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060816022970900_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmg.2007.048991","article-title":"Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)","volume":"44","author":"Vasen","year":"2007","journal-title":"J Med Genet"},{"key":"2022060816022970900_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/GIM.0b013e31818fa2ff","article-title":"Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives","volume":"11","year":"2009","journal-title":"Genet Med"},{"key":"2022060816022970900_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10689-007-9159-3","article-title":"Standards of care in diagnosis and testing for hereditary colon cancer.","volume":"7","author":"Lynch","year":"2008","journal-title":"Fam Cancer"},{"key":"2022060816022970900_bib17","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.296.12.1469","article-title":"Prediction of MLH1 and MSH2 mutations in Lynch syndrome","volume":"296","author":"Balmana","year":"2006","journal-title":"JAMA"},{"key":"2022060816022970900_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1532-0464(02)00006-0","article-title":"Archimedes: a new model for simulating health care systems\u2014the mathematical formulation","volume":"35","author":"Schlessinger","year":"2002","journal-title":"J Biomed Inform"},{"key":"2022060816022970900_bib19","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(09)62162-0","article-title":"Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis","volume":"375","author":"Kahn","year":"2010","journal-title":"Lancet"},{"key":"2022060816022970900_bib20","article-title":"Surveillance Epidemiology and End Results (SEER) Program Populations (1969\u20132006). NCI, DCCPS, Surveillance Research Program","year":"2009","journal-title":"Cancer Statistics Branch"},{"key":"2022060816022970900_bib21","article-title":"Clinical Outcomes Research Initiative","year":"2007"},{"key":"2022060816022970900_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM200007203430301","article-title":"Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380","volume":"343","author":"Lieberman","year":"2000","journal-title":"N Engl J Med"},{"key":"2022060816022970900_bib23","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.2337\/diacare.26.11.3102","article-title":"Validation of the archimedes diabetes model","volume":"26","author":"Eddy","year":"2003","journal-title":"Diabetes Care"},{"key":"2022060816022970900_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0025-5564(01)00052-9","article-title":"A computer model to simulate family history of breast\/ovarian cancer in BRCA1 mutation carriers","volume":"171","author":"Bajdik","year":"2001","journal-title":"Math Biosci"},{"key":"2022060816022970900_bib25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ijc.23508","article-title":"The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome","volume":"123","author":"Watson","year":"2008","journal-title":"Int J Cancer"},{"key":"2022060816022970900_bib26","article-title":"The PREMM 1,2,6 model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history","author":"Kastrinos","year":"2010","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/01.gim.0000237867.34011.12","article-title":"Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention","volume":"8","author":"Ramsey","year":"2006","journal-title":"Genet Med"},{"key":"2022060816022970900_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10689-004-3906-5","article-title":"Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]","volume":"4","year":"2005","journal-title":"Familial Cancer"},{"key":"2022060816022970900_bib29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-145-9-200611070-00006","article-title":"The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening","volume":"145","author":"Gross","year":"2006","journal-title":"Ann Intern Med"},{"key":"2022060816022970900_bib30","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1996.03540160061034","article-title":"Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine","volume":"276","author":"Siegel","year":"1996","journal-title":"JAMA"},{"key":"2022060816022970900_bib31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","article-title":"Willingness to pay for a quality-adjusted life year: in search of a standard","volume":"20","author":"Hirth","year":"2000","journal-title":"Med Decis Making"},{"key":"2022060816022970900_bib32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","article-title":"What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?","volume":"46","author":"Braithwaite","year":"2008","journal-title":"Med Care"},{"key":"2022060816022970900_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2010.0003","article-title":"NCCN clinical practice guidelines in oncology. Colorectal cancer screening","volume":"8","author":"Burt","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"2022060816022970900_bib34","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.292.12.1480","article-title":"Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history","volume":"292","author":"Murff","year":"2004","journal-title":"JAMA"},{"key":"2022060816022970900_bib35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/gut.2003.027896","article-title":"Accuracy of reporting of family history of colorectal cancer","volume":"53","author":"Mitchell","year":"2004","journal-title":"Gut"},{"key":"2022060816022970900_bib36","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1056\/NEJMoa0801297","article-title":"Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome","volume":"359","author":"Burn","year":"2008","journal-title":"N Engl J Med"},{"key":"2022060816022970900_bib37","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s10350-004-7244-3","article-title":"Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families","volume":"45","author":"de Vos tot Nederveen","year":"2002","journal-title":"Dis Colon Rectum"},{"key":"2022060816022970900_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amepre.2006.03.012","article-title":"Priorities among effective clinical preventive services: results of a systematic review and analysis","volume":"31","author":"Maciosek","year":"2006","journal-title":"Am J Prev Med"},{"key":"2022060816022970900_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-133-8-200010170-00007","article-title":"Cost-effectiveness of colonoscopy in screening for colorectal cancer","volume":"133","author":"Sonnenberg","year":"2000","journal-title":"Ann Intern Med"},{"key":"2022060816022970900_bib40","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa043146","article-title":"Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)","volume":"352","author":"Hampel","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060816022970900_bib41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1053\/j.gastro.2007.08.019","article-title":"Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome","volume":"133","author":"Mecklin","year":"2007","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib42","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1200\/JCO.2007.13.2795","article-title":"Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma\/carcinoma prevention programme 2","volume":"26","author":"Liljegren","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060816022970900_bib43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/gut.50.2.228","article-title":"Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer","volume":"50","author":"Lindgren","year":"2002","journal-title":"Gut"},{"key":"2022060816022970900_bib44","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/gut.50.3.382","article-title":"Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation","volume":"50","author":"Rijcken","year":"2002","journal-title":"Gut"},{"key":"2022060816022970900_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.gastro.2003.10.043","article-title":"The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC","volume":"126","author":"de Jong","year":"2004","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2353\/jmoldx.2009.080142","article-title":"Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas","volume":"11","author":"Pino","year":"2009","journal-title":"J Mol Diagn"},{"key":"2022060816022970900_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.gastro.2004.03.068","article-title":"Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance","volume":"127","author":"Hendriks","year":"2004","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib48","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1086\/421332","article-title":"Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history","volume":"74","author":"Buttin","year":"2004","journal-title":"Am J Hum Genet"},{"key":"2022060816022970900_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/hmg\/6.1.105","article-title":"Cancer risk associated with germline DNA mismatch repair gene mutations","volume":"6","author":"Dunlop","year":"1997","journal-title":"Hum Mol Genet"},{"key":"2022060816022970900_bib50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jmg.2004.024299","article-title":"Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment","volume":"42","author":"Quehenberger","year":"2005","journal-title":"J Med Genet"},{"key":"2022060816022970900_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/jmg.38.5.318","article-title":"Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree","volume":"38","author":"Wagner","year":"2001","journal-title":"J Med Genet"},{"key":"2022060816022970900_bib52","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.gastro.2008.04.026","article-title":"The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations","volume":"135","author":"Senter","year":"2008","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1399-0004.2008.01035.x","article-title":"Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations","volume":"74","author":"Barrow","year":"2008","journal-title":"Clin Genet"},{"key":"2022060816022970900_bib54","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2009.07.039","article-title":"Calculation of risk of colorectal and endometrial cancer among patients with Lynch Syndrome","volume":"137","author":"Stoffel","year":"2009","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib55","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM199805213382101","article-title":"Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease","volume":"338","author":"Aaltonen","year":"1998","journal-title":"N Engl J Med"},{"key":"2022060816022970900_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM200001133420201","article-title":"Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer","volume":"342","author":"Gryfe","year":"2000","journal-title":"N Engl J Med"},{"key":"2022060816022970900_bib57","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1056\/NEJMoa053493","article-title":"Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer","volume":"354","author":"Barnetson","year":"2006","journal-title":"N Engl J Med"},{"key":"2022060816022970900_bib58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.0.CO;2-L","article-title":"Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members","volume":"83","author":"Watson","year":"1998","journal-title":"Cancer"},{"key":"2022060816022970900_bib59","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/gast.1996.v110.pm8608876","article-title":"Better survival rates in patients with MLH1-associated hereditary colorectal cancer","volume":"110","author":"Sankila","year":"1996","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/07853899808999387","article-title":"Prognosis of colorectal cancer varies in different high-risk conditions","volume":"30","author":"Aarnio","year":"1998","journal-title":"Ann Med"},{"key":"2022060816022970900_bib61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1091-255X(98)80105-4","article-title":"Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer","volume":"2","author":"Lin","year":"1998","journal-title":"J Gastrointest Surg"},{"key":"2022060816022970900_bib62","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF02555012","article-title":"Clinical features of colorectal carcinoma in cancer family syndrome","volume":"29","author":"Mecklin","year":"1986","journal-title":"Dis Colon Rectum"},{"key":"2022060816022970900_bib63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000658-199702000-00008","article-title":"Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC","volume":"225","author":"Rodriguez-Bigas","year":"1997","journal-title":"Ann Surg"},{"key":"2022060816022970900_bib64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.gastro.2005.05.011","article-title":"Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset","volume":"129","author":"Hampel","year":"2005","journal-title":"Gastroenterology"},{"key":"2022060816022970900_bib65","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L","article-title":"Cancer risk in mutation carriers of DNA-mismatch-repair genes","volume":"81","author":"Aarnio","year":"1999","journal-title":"Int J Cancer"},{"key":"2022060816022970900_bib66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.cgh.2006.01.002","article-title":"Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study","volume":"4","author":"Jenkins","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022060816022970900_bib67","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12094-008-0206-9","article-title":"Gynecologic cancers associated with Lynch syndrome\/HNPCC","volume":"10","author":"Schmeler","year":"2008","journal-title":"Clin Transl Oncol"},{"key":"2022060816022970900_bib68","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ijc.10667","article-title":"Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer","volume":"102","author":"Boks","year":"2002","journal-title":"Int J Cancer"},{"key":"2022060816022970900_bib69","first-page":"353","article-title":"Colonoscopy: a review of its yield for cancers and adenomas by indication","volume":"90","author":"Rex","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"2022060816022970900_bib70","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1097-0142(20001015)89:8<1765::AID-CNCR17>3.0.CO;2-F","article-title":"The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis","volume":"89","author":"Dijkhuizen","year":"2000","journal-title":"Cancer"},{"key":"2022060816022970900_bib71","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/cncr.10380","article-title":"The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma","volume":"94","author":"Dove-Edwin","year":"2002","journal-title":"Cancer"},{"key":"2022060816022970900_bib72","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1136\/jmg.40.5.e54","article-title":"Cancer surveillance is often inadequate in people at high risk for colorectal cancer","volume":"40","author":"Stoffel","year":"2003","journal-title":"J Med Genet"},{"key":"2022060816022970900_bib73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10689-005-0658-9","article-title":"Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures","volume":"4","author":"Wagner","year":"2005","journal-title":"Fam Cancer"},{"key":"2022060816022970900_bib74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/cncr.21183","article-title":"Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma","volume":"104","author":"Collins","year":"2005","journal-title":"Cancer"},{"key":"2022060816022970900_bib75","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.GIM.0000086626.03082.B5","article-title":"An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer","volume":"5","author":"Ramsey","year":"2003","journal-title":"Genet Med"},{"key":"2022060816022970900_bib76","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cncr.23554","article-title":"Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome","volume":"113","author":"Kwon","year":"2008","journal-title":"Cancer"},{"key":"2022060816022970900_bib77","article-title":"Cost-effectiveness of DNA stool testing to screen for colorectal cancer: Report to Agency for Healthcare Research and Quality (AHRQ) and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models","author":"Zauber","year":"2007"},{"key":"2022060816022970900_bib78","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1572-0241.1999.01157.x","article-title":"Utility valuations for outcome states of colorectal cancer","volume":"94","author":"Ness","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"2022060816022970900_bib79","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1365-2168.2000.01442.x","article-title":"Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis","volume":"87","author":"Van Duijvendijk","year":"2000","journal-title":"Br J Surg"},{"key":"2022060816022970900_bib80","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1524-4733.2008.00352.x","article-title":"Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available)","volume":"11","author":"Ara","year":"2008","journal-title":"Value Health"},{"key":"2022060816022970900_bib81","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2005.07.102","article-title":"Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer","volume":"23","author":"Gritz","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022060816022970900_bib82","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/GIM.0b013e3181cd666c","article-title":"The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer","volume":"12","author":"Mvundura","year":"2010","journal-title":"Genet Med"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/4\/1\/9\/2336855\/9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/4\/1\/9\/2336855\/9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T13:18:13Z","timestamp":1654694293000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/4\/1\/9\/49732\/Health-Benefits-and-Cost-Effectiveness-of-Primary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,3]]},"published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-10-0262","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1940-6207.22524444.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22524444","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6544254","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22524447","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22524447.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6544254.v1","asserted-by":"object"}]},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,1]]}}}